Mechanisms of resistance to immune checkpoint inhibitors and strategies to reverse drug resistance in lung cancer / 中华医学杂志(英文版)
Chinese Medical Journal
;
(24): 2444-2455, 2020.
Artigo
em Inglês
| WPRIM
| ID: wpr-877859
ABSTRACT
In recent years, the research of immune checkpoint inhibitors has made a great breakthrough in lung cancer treatment. Currently, a variety of immune checkpoint inhibitors have been applied into clinical practice, including antibodies targeting the programmed cell death-1, programmed cell death-ligand 1, and cytotoxic T-lymphocyte antigen 4, and so on. However, not all patients can benefit from the treatment. Abnormal antigen presentation, functional gene mutation, tumor microenvironment, and other factors can lead to primary or secondary resistance. In this paper, we reviewed the molecular mechanism of immune checkpoint inhibitor resistance and various combination strategies to overcome resistance, in order to expand the beneficial population and enable precision medicine.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Resistência a Medicamentos
/
Microambiente Tumoral
/
Antígeno B7-H1
/
Antígeno CTLA-4
/
Inibidores de Checkpoint Imunológico
/
Imunoterapia
/
Neoplasias Pulmonares
Limite:
Humanos
Idioma:
Inglês
Revista:
Chinese Medical Journal
Ano de publicação:
2020
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS